Callan Family Office LLC Purchases 117,174 Shares of Elanco Animal Health Incorporated $ELAN

Key Points

• Callan Family Office LLC significantly increased its stake in Elanco Animal Health, acquiring an additional 117,174 shares, raising its total holdings to 166,198 shares valued at approximately $2.37 million.
• Wall Street analysts have shown optimism for Elanco Animal Health, with multiple upgrades in ratings, resulting in a consensus rating of "Moderate Buy" and an average target price of $19.14.
• Elanco reported a 4.8% year-over-year revenue increase, with Q2 earnings per share of $0.26, outperforming analysts' expectations by $0.06.

Callan Family Office LLC increased its position in Elanco Animal Health Incorporated (NYSE:ELAN - Free Report) by 239.0% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 166,198 shares of the company's stock after acquiring an additional 117,174 shares during the quarter. Callan Family Office LLC's holdings in Elanco Animal Health were worth $2,373,000 at the end of the most recent quarter.

Other institutional investors have also recently bought and sold shares of the company. Allworth Financial LP raised its holdings in Elanco Animal Health by 791.7% in the 1st quarter. Allworth Financial LP now owns 2,354 shares of the company's stock worth $25,000 after acquiring an additional 2,090 shares during the period. Wealthquest Corp bought a new position in Elanco Animal Health in the 1st quarter worth $56,000. Covestor Ltd raised its holdings in Elanco Animal Health by 510.9% in the 1st quarter. Covestor Ltd now owns 7,087 shares of the company's stock worth $74,000 after acquiring an additional 5,927 shares during the period. MRP Capital Investments LLC raised its holdings in Elanco Animal Health by 60.0% in the 1st quarter. MRP Capital Investments LLC now owns 8,000 shares of the company's stock worth $84,000 after acquiring an additional 3,000 shares during the period. Finally, Parallel Advisors LLC raised its holdings in Elanco Animal Health by 66.6% in the 2nd quarter. Parallel Advisors LLC now owns 6,432 shares of the company's stock worth $92,000 after acquiring an additional 2,572 shares during the period. Institutional investors own 97.48% of the company's stock.

Wall Street Analysts Forecast Growth

Several research analysts have recently issued reports on ELAN shares. Zacks Research upgraded shares of Elanco Animal Health from a "hold" rating to a "strong-buy" rating in a report on Friday, October 3rd. Leerink Partners upgraded shares of Elanco Animal Health from a "market perform" rating to an "outperform" rating and set a $18.00 price objective on the stock in a report on Thursday, July 17th. UBS Group boosted their price objective on shares of Elanco Animal Health from $18.00 to $19.00 and gave the stock a "buy" rating in a report on Friday, August 8th. Wall Street Zen upgraded shares of Elanco Animal Health from a "hold" rating to a "buy" rating in a report on Saturday, July 5th. Finally, William Blair upgraded shares of Elanco Animal Health from a "market perform" rating to an "outperform" rating in a report on Thursday, June 26th. Two analysts have rated the stock with a Strong Buy rating, six have given a Buy rating and three have given a Hold rating to the company. According to MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $19.14.

Elanco Animal Health Stock Performance

NYSE ELAN opened at $19.77 on Friday. The stock has a market cap of $9.82 billion, a P/E ratio of 22.99, a PEG ratio of 3.64 and a beta of 1.65. The company's 50-day simple moving average is $18.35 and its 200 day simple moving average is $14.43. Elanco Animal Health Incorporated has a twelve month low of $8.02 and a twelve month high of $21.76. The company has a quick ratio of 1.40, a current ratio of 2.60 and a debt-to-equity ratio of 0.61.

Elanco Animal Health (NYSE:ELAN - Get Free Report) last posted its earnings results on Thursday, August 7th. The company reported $0.26 earnings per share for the quarter, beating analysts' consensus estimates of $0.20 by $0.06. The business had revenue of $1.24 billion for the quarter, compared to analysts' expectations of $1.19 billion. Elanco Animal Health had a net margin of 9.68% and a return on equity of 7.04%. The firm's revenue for the quarter was up 4.8% on a year-over-year basis. During the same quarter in the previous year, the firm posted $0.30 earnings per share. Elanco Animal Health has set its Q3 2025 guidance at 0.120-0.160 EPS. FY 2025 guidance at 0.850-0.91 EPS. As a group, research analysts forecast that Elanco Animal Health Incorporated will post 0.91 earnings per share for the current fiscal year.

Elanco Animal Health Company Profile

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.